KANATA, Ontario--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide.
Puppo brings a wealth of experience to BWXT Medical, with over 30 years of experience in the areas of imaging, nuclear medicine, radiation therapy and biotech, in both Europe and North America. In his most recent roles, he served as chief operating officer of Radiopharm Theranostics and held various positions with Bracco. These include chief marketing and strategy officer of Bracco Imaging, president and chief executive officer of Bracco Diagnostics Inc., interim head of Corporate Business Development and global head of Injectors Business Unit. Prior to Bracco, Puppo held various senior level positions with Accuray, Covidien (now part of Medtronic) and Amersham (now part of GE Healthcare).
“Vittorio’s extensive experience, strategic insight and commitment to the medical manufacturing industry make him an ideal fit to lead our medical business into its next phase of growth and innovation,” said John MacQuarrie, president of BWXT commercial operations. “We’re confident that, under his leadership, BWXT Medical will continue to thrive and deliver increasing value to our customers and collaborators.”
“I am honored to join BWXT Medical and lead such a talented team dedicated to making a positive impact in the healthcare industry,” said Puppo. “I look forward to building on the company’s strong foundation and driving forward its vision of innovation, quality and customer-centricity. Together, we will continue to develop cutting-edge medical solutions that address the evolving needs of our customers, healthcare providers and their patients.”
Puppo holds a degree in finance and economics and a Master of Business Administration from the SDA Bocconi School of Management in Italy. He held the position of vice president of the European Association of Imaging Producers and Equipment Suppliers between 2004 and 2008, and has been a board member of the Medical Imaging and Technology Alliance since 2021.
Puppo succeeds Jonathan Cirtain, whose expertise and dedication have been instrumental to BWXT Medical’s progress to-date. Cirtain will transition back full-time into his role as BWXT’s chief development officer, continuing to support BWXT Medical, along with the company’s broader innovation goals.
About BWXT Medical Ltd.
BWXT Medical Ltd. manufactures custom radiopharmaceuticals, radiotherapies and medical isotopes in an 80,000-square-foot cGMP manufacturing facility in Ottawa and at the state-of-the-art commercial cyclotron facility within TRIUMF, Canada’s particle acceleration centre. BWXT Medical Ltd. is a subsidiary of BWX Technologies, Inc. (NYSE: BWXT). BWXT is a manufacturing and engineering innovator that provides safe and effective nuclear solutions for global security, clean energy, environmental restoration, nuclear medicine and space exploration. Learn more at www.bwxtmedical.com and follow us on LinkedIn.
